mRNA-based cancer vaccine simultaneously targeting multiple KRAS mutations induces robust anti-tumor immune responses in various KRAS mutant cancers

Harnessing mRNA-based therapy to restore p53 function to suppress growth of p53 mutant cancers

A novel and potent MAT2A inhibitor, HM100760, demonstrates anti-tumor activity in MTAP-deleted cancers

HM99462, a novel SOS1 inhibitor, induces tumor regression and synergistic effect with KRAS or EGFR targeted therapy in NSCLC

Discovery of potent, selective, and orally bioavailable HER2 tyrosine kinase inhibitors targeting HER2 exon20 insertion mutants and HER2^WT